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Methods: 41consecutive patients (38 men and 3 women; age 52 9 years) with anterior
STEMI were enrolled. All patients were randomized into two groups and underwent
primary PCI for anterior STEMI: stenting after manual thrombectomy (aspiration group,
n22) and stenting without manual thrombectomy (conventional group, n19). The
thermodilution-derived coronary flow reserve (CFR) and index of microcirculatory
resistance (IMR) were measured by using the pressure-temperature sensor-tipped coro-
nary wire at the left anterior descending artery (LAD) after primary PCI. Baseline
echocardiography was performed before discharge and follow-up echocardiography was
performed 6 months later.
Results: There was no significant difference in reperfusion time (onset to balloon time)
and CFR (2.01  1.1 vs. 2.08  1.1, p  0.831), baseline ejection fraction (EF, 44.5 
7.5% vs. 48.0 8.0%, p 0.15), baseline wall motion score index (WMSI, 1.52 0.32
vs. 1.46  0.31, p  0.59) between two groups. But, there was significant difference in
IMR (22.3 8.7 vs. 29.5 11.9, p 0.037), EF (follow up EF – baseline EF, 5.86
7.2 vs. 1.29 2.5, p 0.011), WMSI (baseline WMSI – follow up WMSI,0.199
0.242 vs. 0.003  0.075, p  0.001) between two groups.
Conclusions: Compared with conventional PCI, manual thrombectomy before stenting
for patients with anterior STEMI seems to preserve microvascular integrity. Manual
thrombectomy as an adjunctive method of primary PCI for acute anterior STEMI might
have beneficial efficacy on myocardial microcirculation.
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Background: Drug-eluting stents (DES) are used in ST-segment elevation myocardial
infarction (STEMI) patients with good safety and efficacy, even in complex patient
subsets. This study aimed to compare the in-hospital and 1-year outcomes of STEMI
patients with complex clinical and angiographic characteristics treated with 1st- versus
2nd-generation DES.
Methods: The study included 524 consecutive STEMI patients with1 of the following
characteristics: Ejection fraction (EF) 30%, chronic renal insufficiency (CRI), cardio-
genic shock, bifurcation, unprotected left main, totally occluded, ACC/AHA Type C,
bypass graft, in-stent restenosis, presence of thrombus, 1 lesion treated, and stent
implantation length 28 mm. Clinical outcomes of patients treated with 1st-generation
DES (Cypher/Taxus) (n452) were compared to those treated with 2nd-generation DES
(Promux/Xience) (n102).
Results: Baseline demographics were similar in patients treated with 1st- vs. 2nd-
generation DES. Mean age was 62.2  12.5 years; 65% males; mean EF was 42  13
%; and 13.1% had CRI. IABP use (14.2% overall), procedure time (50 51 min overall),
lesion locations, graft and in-stent restenosis lesions were also similar. 2nd-generation
DES were used more frequently in Type C lesions (56.8 vs. 27.4 %, p0.001) and distal
lesions (25.2 vs. 13.8 %, p0.001). The number of implanted DES was 1.5  0.8
overall. Angiographic success was similar at 99.4% overall. There was no difference in
composite major in-hospital complications. 1-year mortality, revascularization, and major
adverse cardiac event rates were similar in both groups.(Table)
1st
generation
DES
2nd
generation
DES
P value(n452) (n102)
In-hospital Death 4.2 (19) 1 (1) 0.146
In-hospital Q-wave MI 0.4 (2) 0 (0) 1
In-hospital Urgent CABG 0.4 (2) 4 (4) 0.012
In-hospital Stent thrombosis 0.4 (2) 0 (0) 1
Major in-hospital complications
(death/QWMI/CABG)
4.9 (22) 4.9 (5) 1
1-year Death 10.3 (46) 6.9 (7) 0.305
1-year Q-wave MI 0.2 (19) 1 (1) 0.339
1-year Target Lesion
Revascularization
5.2 (22) 4.1 (4) 0.8
1-year Target Vessel
Revascularization
9.2 (39) 8.2 (8) 0.747
1-year Stent thrombosis 0.9 (4) 0 (0) 1
1-year MACE (Death/QWMI/
TVR)
17.9 (81) 14.7 (15) 0.438
Conclusions: Despite the presence of higher lesion complexity, the use of 2nd-generation
DES in a STEMI population with complex clinical and angiographic characteristics
results in similarly low rates of in-hospital and 1-year outcomes when compared to
1st-generation DES.
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Background: Troponin elevation is a risk factor for mortality in pts with non
ST-segment elevation acute coronary syndromes (NSTEACS). However, prognostic
impact of non-obstructive coronary artery disease (CAD) in NSTEACS pts with troponin
elevation is unknown.
Methods: In the ACUITY trial, 3-vessel quantitative coronary angiography was
performed in a formal substudy of 6,921 pts with moderate and high-risk NSTEACS.
Patients with elevated admission troponin levels ( local upper limit of normal) were
stratified by the presence or absence of obstructive CAD (any lesion with diameter
stenosis (DS) 50%). Propensity-score matching was performed to adjust for baseline
characteristics.
Results: Of 2,442 patients with elevated troponins, 197 (8.8%) had non-obstructive
CAD. Maximum DS was 83.5%  17.5 vs. 24.1%  12.2 (p0.0001) in pts with vs.
without obstructive CAD. Propensity score matching yielded 117 patients with non-
obstructive CAD and 351 patients with obstructive CAD with no significant baseline
differences including renal function and diabetes. Overall 1-year mortality was signifi-
cantly higher in pts with non-obstructive CAD (5.2% vs 1.2%; HR [95%CI]  4.57
[1.29,16.21], p0.01), driven mainly by higher non-cardiac mortality (Table). Con-
versely, recurrent MI and unplanned revascularization rates were higher in patients with
obstructive CAD.
Non-
obstructive
CAD
(n117)
Obstructive
CAD
(n351)
Relative Risk
[95% CI] P-Value
1 Month Outcomes
Death 2.6% (3) 0.3% (1) 9.07 [0.94,87.15] 0.02
Cardiac death 0.9% (1) 0.3% (1) 3.02 [0.19,48.24] 0.41
Non-cardiac death 1.7% (2) 0.0% (0) N/A 0.01
Recurrent MI 0.9% (1) 6.3% (22) 0.13 [0.02,1.00] 0.02
Unplanned revascularization 0.0% (0) 3.7% (13) N/A 0.04
Major bleeding 5.2% (6) 6.0% (21) 0.86 [0.35,2.12] 0.74
CVA/TIA 0.0% (0) 0.3% (1) N/A 1.00
1-Year Outcomes
Death 5.2% (6) 1.2% (4) 4.57 [1.29,16.21] 0.01
Cardiac death 1.7% (2) 0.9% (3) 2.03 [0.34,12.16] 0.43
Non-cardiac death 3.5% (4) 0.3% (1) 12.20 [1.4,109.1] 0.004
Recurrent MI 3.6% (4) 9.0% (31) 0.38 [0.13,1.08] 0.058
Unplanned revascularization 0.0% (0) 9.2% (31) N/A 0.001
CVA/TIA 0.0% (0) 0.3% (1) N/A 1.00
Conclusions: Patients presenting with NSTEACS symptoms and elevated troponin
levels in whom obstructive CAD is absent, are at significantly higher risk of 1-year
all-cause and non-cardiac mortality than those with obstructive CAD, despite lower rates
of unplanned revascularization and subsequent MI. Troponin elevation in pts with
non-obstructive CAD may be an important risk factor for mortality, prompting a
comprehensive search for an alternative diagnosis.
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Background: Mortality amongst emergency medical admissions has been reported to be
higher when patients are admitted to hospital at nights and weekends. We studied the
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mortality for STEMI patients presenting at different times to a large cardiothoracic center
in the UK with a 24/7 primary PCI (PPCI) service delivered by senior medical staff.
Methods: We included all patients who underwent PPCI from September 2009 to
November 2011. We divided them into three groups according to the time of admission
to our unit as group 1: in-hours (8 am to 6 pm weekdays), group 2: out-of-hours (6 pm
to 8 am week nights) and group 3: weekend (Saturday 8 am to Monday 8 am) and bank
holidays.
Results: Of the 1471 patients admitted and underwent PPCI in our unit during the study
period, 605 (41.1%), 397 (27%) and 469 (31.9%) were included in group 1, 2 and 3
respectively. Pre-procedure cardiogenic shock was significantly higher in group 1
compared to group 2 (8.9% vs 5.5%, p 0.05), but no other significant difference was
noted in the baseline and procedural characteristics between the groups (Table 1). When
compared to group 1, door to balloon (DTB) time (median, IQR: 29, 24-39 mins) was
significantly prolonged in group 2 (33, 24-36 mins, p0.004) and group 3 (36, 28-47
mins, p0.0001). There was no difference in DTB time between groups 2 and 3
(p0.15). However, there was no significant difference in in-hospital mortality (grp 1 vs
grp 2 vs grp3: 4.6% vs 4.3% vs 5.3%, p NS), 30-day mortality (6.4% vs 6.3% vs 7%, p
NS) or stent thrombosis (0.8% vs 0.8% vs 0.2%, p NS) between the groups.
Variable
In hours (8 am
to 6 pm
weekdays)
Out of hrs (6pm
to 8 am
weekdays)
Weekendbank
Holidays
N (%) N 605 N 397 N 469
Age (meanSD) 6514 6613 6513
Age 75 yrs 164 (27.1) 97 (24.4) 115 (24.5)
Female 168 (27.8) 114 (28.7) 118 (25.2)
Diabetes 70 (11.6) 49 (12.3) 55 (11.7)
Cardiogenic shock 54 (8.9) 22 (5.5) 36 (7.7)
Previous MI 70 (11.6) 56 (14.1) 51 (10.9)
Previous CABG 16 (2.6) 15 (3.8) 5 (1.1)
Previous PCI 37 (6.1) 28 (7.1) 31 (6.6)
Single vessel PCI 545 (90.1) 356 (89.7) 412 (87.8)
Drug eluting stent
(at least one)
361 (59.7) 236 (59.4) 278 (59.3)
Conclusions: In this consecutive series of patients admitted to a high volume primary
PCI center, there was no difference in mortality when patients were admitted at night, at
the weekend or during regular office hours. The involvement of senior medical staff early
in the patients’ admission may have contributed to these consistent outcomes.
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Background: Bare metal (BMS) and drug eluting stents have shown to reduce repeat
target lesion revascularization in primary percutaneous coronary intervention (PPCI),
however this did not result in a reduction of recurrent myocardial infarction or mortality
rates. Furthermore, there are concerns of the occurrence of stent thrombosis. As a novel
treatment modality, a drug-eluting balloon (DEB) may be a therapeutic challenge, as it can
provide the potential advantage of delivering an anti-proliferative drug without leaving a
coronary stent, hereby not disrupting the physiologic properties of the vessel. Our aim was
to evaluate safety and feasibility of using a CE-marked paclitaxel-eluting balloon in PPCI.
Methods: 100 patients with ST-elevation myocardial infarction (STEMI), eligible for
PPCI, were treated with a DEB only strategy. Bail-out stenting with BMS was allowed
only in case of type C-F coronary dissection or a residual stenosis  50%. All patients
were treated with i.v. bivalirudin, on top of aspirin, heparin and prasugrel. The primary
endpoint of the study was the occurrence of major cardiac adverse events (MACE) at one
month, defined as the composite of cardiac death, recurrent myocardial infarction and
target lesion revascularization. The secondary endpoints contained 6-12 months follow-up
and major bleeding rates.
Results: Of 100 STEMI patients, 59 patients were treated with a DEB only, bail-out
stenting was performed in 41 patients. One-month follow-up was completed in all
patients. A total of 3 MACE was reported within one-month follow-up, all in the DEB
only group. No major bleedings were reported. At 12 months, with complete follow-up in
98%, 2 additional MACE were reported. One patient underwent target vessel revascu-
larization after initial DEB plus bail-out stenting. Another patient, treated with a DEB
only, died due to cardiac death.
Conclusions: This first study to evaluate clinical outcome of the application of a DEB
only strategy in the setting of PPCI for STEMI, showed good short-term results, with
sustained safety and efficacy at 12 months follow-up. A randomized controlled trial is
warranted to evaluate the efficacy of this strategy compared to the current standard of care.
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Background: Apoptosis (AP) has been involved in the physiopathology of acute
myocardial infarction (AMI). The P53 gene plays an essential role in the activation of AP.
Recent studies have shown that the Arg72 variant induces apoptosis markedly better than
does the Pro72 variant. The objective is to analysis the relationship between P53 codon 72
polymorphism (PLs) with the infarct size and the LVEF in patients with ST-segment
elevation acute coronary syndrome (STE-ACS) undergoing primary angioplasty.
Methods: DNA of 91 patients with STE-ACS. The PLs were identified by polymerase
chain reaction and restriction enzyme analysis. Patients were divided into three groups
(homozygous arginine –AA–, heterozygous arginine/proline –AP– and homozygous
proline –PP–). The infarct size was estimated of infarct with the peak serum concentra-
tions of CK and CK-MB. LVEF was determined by 2D echocardiography.
Results: 63 men (69%) and 28 women (31%), with an average age of 72 13 years. The
prevalence of AA, AP and PP PLs was of 51, 41 and 8%, respectively. No significant
differences were found regarding the demographical, clinical and pharmacology treatment
characteristics in the three groups. The artery responsible for the AMI was the right
coronary (46%), left anterior descending (38%), left circumflex (14%) and left main
coronary artery (2%). A bare metal stent was implanted in a 40% and drug eluting stent
in 58% and the final TIMI-flow achieved was 2 in 89% of the patients. Peak levels of
CK (AA 1644  1586 vs AP 1273  1197 vs PP 323 177 U/L; p 0.02) and CK-MB
(AA 128  114 vs AP 97  93 vs PP 22  13 U/L; p 0.04) were significantly higher in
homozygous AA patients. The LVEF (AA 498, AP 547, PP 596 %, p 0.001) were
significantly lower in homozygous AA patients. We carried out a multivariate logistic
regression analysis and the AA PL remained as an independent predictor for size of infarct
(p 0.025) and the LVEF (p 0.001).
Conclusions: Patients with STE-ACS homozygous AA for the codon 72 of gene P53 has
a larger infarct size and lower LVEF compared to the non-homozygous AA.
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Background: We have previously shown that a diameter stenosis (DS) of 50% is
optimal to define incomplete coronary revascularization (ICR) in pts with ACS undergo-
ing PCI. However, the optimal reference vessel diameter (RVD) is unknown. We
therefore explored the prevalence and impact of ICR in ACUITY according to different
RVDs.
Methods: Quantitative coronary angiography (QCA) of the entire coronary tree was
performed in 2954 PCI pts with UA/NSTEMI in ACUITY. ICR was defined present if
any lesion with a final DS 50% by QCA was left untreated in any coronary segment,
with the minimal RVD ranging from 1.5 mm to 3.0 mm in 0.25 mm increments. The
primary outcome measure was 1-year rate of major adverse cardiac events (MACE: death,
MI or unplanned revascularization).
Results: Using RVD cutoffs of1.5 mm,1.75 mm,2.0 mm,2.25 mm,2.5 mm,
2.75 mm and 3.0 mm the prevalence of ICR after PCI was 51%, 45%, 37%, 29%,
21%, 14% and 10% respectively. 1-year MACE was increased among pts with ICR using
all the RVD cutoffs (Table). Sensitivity and specificity curves for RVD in 0.05mm
increments were constructed to define ICR for the occurrence of 1-year MACE. The
overlap point of the curves was at QCA RVD 1.75 mm (visually estimated RVD 2.0
mm). Using a QCA RVD 1.75 mm to define ICR, ICR was associated with higher
1-year rates of MACE (22.8% vs. 16.2%, HR[95%CI] 1.47 [1.24,1.74], P0.0001), MI
(11.9% vs. 7.7%, HR[95%CI]  1.58 [1.25,2.00], p0.0001) and unplanned revascular-
ization (15.2% vs. 9.8%, HR[95%CI] 1.60 [1.29,1.98], p0.0001), with a trend toward
increased mortality (3.0% vs. 2.2%, HR[95%CI]  1.39 [0.88,2.21], p0.16).
Conclusions: Depending on the RVD, ICR was present in 10%-51% of pts with ACS
after PCI. Regardless of the definition, ICR was associated with 1-year MACE, with a
QCA RVD of 1.75 mm (visually estimated RVD 2.0 mm) representing the optimal
cutoff to balance sensitivity and specificity.
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